Does Cosentyx Cause Weight Gain?
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, lists weight gain as an uncommon side effect in its prescribing information. Clinical trials reported it in 1-5% of patients, typically mild increases of 5-10% body weight over 52 weeks, compared to placebo rates under 1%. Post-marketing data shows rare cases of significant gain, but no causal link is proven—factors like improved mobility from reduced joint pain or concurrent medications often contribute.[1][2]
How Common Is Weight Gain on Cosentyx?
In pivotal trials (e.g., FUTURE and MEASURE studies):
- Psoriatic arthritis: 2.4% of Cosentyx users vs. 1.1% placebo gained ≥5% body weight.
- Ankylosing spondylitis: Up to 4% incidence.
Real-world registries like CorEvitas report similar rates (around 3%), with most gains stabilizing after 6-12 months. Women and those with baseline obesity face slightly higher risk.[3][4]
Why Might Weight Gain Happen?
No direct mechanism ties Cosentyx to weight gain. Theories include:
- Reduced inflammation allowing better appetite or activity.
- IL-17 inhibition indirectly affecting metabolism, though unconfirmed.
- Confounding from steroids or lifestyle changes post-treatment. Studies show no metabolic syndrome worsening.[2][5]
What Do Patient Reviews Say?
On forums like Drugs.com and PatientsLikeMe, about 5-10% of Cosentyx users report weight gain (average 5-15 lbs over 6 months), often describing it as unexpected but manageable. Many attribute it to eating more due to symptom relief. Positive reviews dominate (rating ~7/10), with weight concerns rarely leading to discontinuation.[6]
How Does This Compare to Other Biologics?
| Drug | Weight Gain Rate (Trials) | Notes |
|------|---------------------------|-------|
| Cosentyx | 1-5% | Mild, uncommon |
| Humira (adalimumab) | 3-7% | Similar, dose-related |
| Stelara (ustekinumab) | <2% | Lowest among IL inhibitors |
| Enbrel (etanercept) | 2-4% | Often linked to fatigue relief |
| Tremfya (guselkumab) | 1-3% | Comparable profile |
Cosentyx aligns with class averages; no biologic is weight-neutral.[3][7]
What Should Users Do If Experiencing Gain?
Monitor BMI quarterly. Doctors recommend diet tracking and exercise. Switching biologics resolves it in ~60% of cases per observational data. No black-box warning exists.[1][4]
Sources:
[1]: Cosentyx Prescribing Information (Novartis)
[2]: FDA Label for Secukinumab
[3]: FUTURE 5 Trial (Lancet, 2018)
[4]: CorEvitas PsA Registry Data (2022)
[5]: IL-17 and Metabolism Review (JCI Insight, 2020)
[6]: Drugs.com Cosentyx Reviews
[7]: Biologic Safety Meta-Analysis (JAMA Dermatol, 2021)